Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT06660654
A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThe purpose of this research is to learn more about and investigational drug called raludotatug deruxtecan, hereafter referred to as D-DXd. it is being studies to see if it is effective, tolerable...
-
NCT05514717
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: Celebration -
NCT06172478
A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThe purpose of this study is to learn more about an investigational drug called patritumab deruxtecan (also known as HER3-DXd or U3-1402), also referred to as “study drug” or “study treatment”...
-
NCT06307795
A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThis is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in...
-
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationYou are being invited to take part in this study because you have been diagnosed with a type of cancer that may express a protein called nectin-4, which LY4101174 is designed to treat and you have...
-
NCT05914116
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThe main goal of this study is to test whether the study drug is safe and tolerable in patients with advanced/unresectable, or metastatic solid tumors (including small cell lung cancer, non-small cell...
-
NCT05520099
Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: Orlando -
NCT05592626
CP-START-001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThe purpose of this research study is
To test the safety of study drug STAR0602. To see how well different doses of the study drug STAR0602 are tolerated in different groups of patients. To understand... -
NCT06026410
KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThe purposes of this study are to:
• Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib.
• Determine whether KO-2806 has an antitumor effect... -
NCT04956640
LOXO-RAS-20001: A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe main purpose of this research study (during both monotherapy and combination therapy evaluation) includes the following: To determine whether LY3537982 is safe; To identify which dose level of...
-
NCT04561362
BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: Celebration -
NCT05614739
AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationAN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS